RELMADA THERAPEUTICS
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.()
RELMADA THERAPEUTICS
Industry:
Biotechnology Clinical Trials Pharmaceutical
Founded:
2004-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.relmada.com
Total Employee:
11+
Status:
Active
Contact:
646-876-3459
Email Addresses:
[email protected]
Total Funding:
183.13 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager Google Universal Analytics Apache Global Site Tag
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
NovaBay Pharmaceuticals
NovaBay Pharmaceuticals is a biopharmaceutical company developing products for the eye care market.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Employees Featured
Founder
Stock Details
Investors List
BioAdvance
BioAdvance investment in Post-IPO Equity - Relmada Therapeutics
BioAdvance
BioAdvance investment in Venture Round - Relmada Therapeutics
BioAdvance
BioAdvance investment in Series A - Relmada Therapeutics
Ben Franklin Technology Partners of Southeastern Pennsylvania
Ben Franklin Technology Partners of Southeastern Pennsylvania investment in Series A - Relmada Therapeutics
BioAdvance
BioAdvance investment in Seed Round - Relmada Therapeutics
Official Site Inspections
http://www.relmada.com Semrush global rank: 1.06 M Semrush visits lastest month: 31.66 K
- Host name: ec2-54-208-101-55.compute-1.amazonaws.com
- IP address: 54.208.101.55
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Relmada Therapeutics"
Relmada Therapeutics, Inc. (RLMD)
Nov 7, 2024 · Relmada Therapeutics is dedicated to improving the standard of care for central nervous system (CNS) disorders. Our primary focus is the mental health space as we advance …See details»
Our story :: Relmada Therapeutics, Inc. (RLMD)
At Relmada Therapeutics, we focus on the research and development of transformative medicines for those living with central nervous system (CNS) disorders. Our company name stems from the word "relief" and represents our …See details»
Relmada Therapeutics Provides Corporate Update and Reports …
Mar 23, 2023 · Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels …See details»
Relmada Therapeutics, Inc - LinkedIn
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and...See details»
Relmada Therapeutics - The Org
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new …See details»
Relmada Therapeutics, Inc. (RLMD) - Yahoo Finance
See the company profile for Relmada Therapeutics, Inc. (RLMD) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Relmada Therapeutics Provides Corporate Update - PR Newswire
Jan 4, 2024 · Company Well-Positioned for a Pivotal 2024 with Multiple Key Clinical Development Milestones Anticipated. Relmada's Strong Balance Sheet to Support the Company Through All …See details»
Relmada Therapeutics Provides Corporate Update - BioSpace
Jan 4, 2024 · Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). …See details»
News :: Relmada Therapeutics, Inc. (RLMD)
Jun 18, 2024 · Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive DisorderSee details»
Relmada Therapeutics - Crunchbase Company Profile …
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making …See details»
Relmada Therapeutics, Inc. (RLMD) Company Profile & Overview
Nov 18, 2024 · Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and …See details»
Relmada Therapeutics Provides Corporate Update and Reports …
NEW YORK, March 23, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), …See details»
Relmada Therapeutics, Inc. (RLMD) - Yahoo Finance
Find the latest Relmada Therapeutics, Inc. (RLMD) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Relmada Therapeutics Provides Regulatory and Development …
Oct 4, 2021 · Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels …See details»
Relmada Therapeutics Reports Third Quarter 2024 Financial …
CORAL GABLES, Fla., Nov. 7, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada", "the Company"), a late-stage biotechnology company addressing diseases …See details»
the Acquisition of Development and Relmada Therapeutics …
Jul 20, 2021 · Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our …See details»
Relmada Therapeutics Provides Corporate Update and Reports …
Jun 30, 2021 · NEW YORK, Aug. 10, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous …See details»
Relmada Therapeutics, Inc. (RLMD) - Yahoo Finance
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other …See details»
Our First Look At Relmada Therapeutics (NASDAQ:RLMD)
Jun 28, 2021 · Relmada Therapeutics, Inc. (NASDAQ:RLMD) is a New York City based biotechnology concern focused on the development of esmethadone for the treatment of …See details»
Relmada Therapeutics Provides Corporate Update and Reports …
Sep 30, 2021 · Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder …See details»